Janssen Pharmaceutical Inc.
NEWS
Janssen Pharmaceutical, a Johnson & Johnson company, along with Legend Biotech, reported results from their LEGEND-2 Phase I/II clinical trial of CAR-T therapy LCAR-B38M. The therapeutic was being investigated in patients with advanced relapsed or refractory (r/r) multiple myeloma.
Argenx, based in Ghent, Belgium, announced a global collaboration and license deal with Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Approval is based on Phase 3 SPARTAN clinical study data which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years
The Garden State joins a long list of governments that have brought charges against opioid makers during an addiction crisis that claims the lives of 116 Americans per day.
Indianapolis-based Eli Lilly pulled another BACE therapy from its pipeline, the company announced in a third-quarter conference call.
Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.
Janssen and Gilead Sciences continue to showcase the potential treatment abilities of their respective HIV treatments. This morning the two companies released 96-week data demonstrating their efficacy and safety that was presented during an HIV conference in the United Kingdom.
Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).
Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
JOBS
IN THE PRESS